Acute ventilatory failure in Lambert-Eaton myasthenic syndrome and its response to 3,4-diaminopyridine

Neurology

Volumn 46, Issue 4, 1996, Pages 1143-1145

  Smith, A Gordon ^a   Wald, John ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DIAMINOPYRIDINE;

ADULT; ARTICLE; AUTOIMMUNITY; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; EATON LAMBERT SYNDROME; EVOKED MUSCLE RESPONSE; FEMALE; HUMAN; MYASTHENIA GRAVIS; PATIENT COMPLIANCE; PRESYNAPTIC INHIBITION; PRIORITY JOURNAL; RESPIRATORY FAILURE;

EID: 0030006306     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.46.4.1143     Document Type: Article

References (15)

1. Lennon, VA, Lambert EH. Autoantibodies bind solubilized calcium channel omega-conotoxin complexes from small cell lung cancer: a diagnostic aid for LEMS. Mayo Clin Proc 1989;64: 1498-1504.
2. Lennon MA, Kryzer TJ, Griesmann GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
3. Gracey DR, Southorn PA. Respiratory failure in Lambert-Eaton myasthenic syndrome. Chest 1987;91:716-718.
4. O'Neill JH, Murray MNF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;111:577-596.
5. Barr CW, Claussen G, Thomas D, Fesenmeier JT, Pearlman RL, Oh SJ. Primary respiratory failure as the presenting symptom in Lambert-Eaton myasthenic syndrome. Muscle Nerve 1993;16:712-715.
6. Anderson TJ, Carroll GJ, Avery SF, Donaldson IM, Parkin PJ. Lambert-Eaton myasthenic syndrome: two cases with typical and atypical features. NZ J Med 1990;103:240-242.
7. Sanders DB, Yong IK, Howard JF, Goetsch CA. Lambert-Eaton syndrome: a clinical and electrophysiological study of a patient treated with 4 aminopyridine. J Neurol Neurosurg Psychiatry 1980;43:978-985.
8. Lundh H, Nilsson O, Rosen I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine and pyridostigmine. Neurology 1984;34:1324-1330.
9. McEvoy K. Diagnosis and treatment of Lambert-Eaton myasthenic syndrome. Neurol Clin 1994;12:387-399.
10. Chalk CH, Murray NMF, Newsom-Davis J, O'Neill JH, Spiro SG. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 1990;40:1552-1556.
11. Takano H, Tanaka M, Koike R, Nagai J, Arakawa M, Tsuji S. Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 1994;17:1073-1075.
12. Bird S. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 1992;42:1422-1423.
13. Newsom-Davis J, Murray N, Wray D, et al. Lambert-Eaton-myasthenic syndrome: electrophysiologic evidence for a humoral factor. Muscle Nerve 1982;5(Suppl 9):17-20.
14. Murray K, Newsom Davis J. Treatment with 4-aminopyridine in disorders of neuromuscular transmission. Neurology 1981; 31:265-271.
15. McEvoy K, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 1989;321:1567-1571.